Porter Alliance for Innovative Medicines will be equipped with $130m to advance research from Stanford’s Innovative Medicines Accelerator.
Stanford University and investment firm Deerfield Management entered into a collaboration agreement yesterday and launched Porter Alliance for Innovative Medicines with up to $130m in capital.
Porter Alliance will look to accelerate translational research, particularly from Stanford’s Innovative Medicines Accelerator, into clinical therapeutics.
It is the latest such collaboration that Deerfield has inked over the past several years. James Flynn, managing partner at Deerfield, previously spoke to Global University…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
